From the Media

November 15, 2022

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

Read More

October 18, 2022

NeuroSense Therapeutics Provides CEO’s Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

Read More

August 2, 2022

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

Read More

July 28, 2022

NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI

Read More

July 18, 2022

NeuroSense Therapeutics CEO Provides Key Corporate Update Video

Read More

June 30, 2022

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study

Read More

June 27, 2022

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

Read More

June 1, 2022

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

Read More

April 12, 2022

NeuroSense initiates subject dosing in PK study of ALS asset

Read More

April 6, 2022

NeuroSense Therapeutics – Study of New Drug to Treat ALS

Read More

March 31, 2022

Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market

Read More

March 21, 2022

NeuroSense Shares Surge Over 400% As FDA Clears Initiating PK Study Of PrimeC

Read More

December 13, 2021

NeuroSense initiates subject dosing in pharmacokinetics study of ALS asset

Read More

December 8, 2021

NeuroSense Therapeutics Announces Pricing of $12 Million Initial Public Offering

Read More

March 3, 2021

Neurosense Completes Successful Phase IIA And Receives Patent Allowance

Read More

January 12, 2021

Neurosense Granted European Orphan Drug Designation

Read More

January 7, 2021

Neurosense’s Origins, Current Status And Plans Forward

Read More

December 10, 2020

Neurosense Presents At ALS/MND Symposium

Read More

November 18, 2020

Continuation Of Positive Trends In Als Clinical Trial

Read More

September 30, 2020

Neurosense’s Clinical Trial Interim Results Webinar

Read More

Join Our Newsletter